Next-generation inhaled insulin - Nektar Therapeutics

Drug Profile

Next-generation inhaled insulin - Nektar Therapeutics

Alternative Names: NGI; NKTR-034

Latest Information Update: 14 Apr 2008

Price : $50

At a glance

  • Originator Nektar Therapeutics
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 09 Apr 2008 Discontinued - Phase-I for Diabetes mellitus in USA (Inhalation)
  • 14 Nov 2007 Phase-I clinical trials in Diabetes mellitus in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top